ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study
August 28, 2024Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk. -
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues
July 24, 2024Currax Pharmaceuticals LLC announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union and European Union Economic Areas.
Pharma Sources Insight January 2025
